Enclomiphene

What it is

Enclomiphene citrate is an oral selective estrogen receptor modulator (SERM) — specifically the purified trans-isomer of clomiphene citrate — used to raise a man's own testosterone production in secondary (hypogonadotropic) hypogonadism while preserving sperm production, in contrast to exogenous testosterone, which suppresses it.¹ It's sometimes described as "restoring" rather than "replacing" testosterone, since it works by stimulating the body's own hormonal axis instead of substituting for it.

Also known as: it was developed under the brand name Androxal by Repros Therapeutics but was never brought to market in the US after the FDA declined to approve it. Today, it's available only through 503A compounding pharmacies, sometimes marketed by telehealth or longevity clinics as a compounded formulation.⁹

Enclomiphene is one of two components of clomiphene citrate (the other being zuclomiphene) — the FDA-approved racemic mixture used for ovulation induction in women. Isolating enclomiphene from the mixture was intended to capture the beneficial, testosterone-raising effect while minimizing the longer-acting isomer's contribution to side effects, though that isomer-specific benefit has never been definitively proven in a head-to-head trial.¹⁰

How it works

Enclomiphene is a competitive estrogen receptor antagonist at the hypothalamus and pituitary. Normally, estradiol — produced from testosterone through aromatization — tells the brain to dial back GnRH and pituitary LH/FSH output. By blocking estrogen receptor signaling in the brain, enclomiphene interrupts that feedback loop, which increases pulsatile GnRH release, boosts pituitary LH and FSH secretion, and drives the testes to make more of their own testosterone while supporting sperm production through FSH's effect on Sertoli cells.¹

This is a fundamentally different mechanism than testosterone replacement, which suppresses LH/FSH, and it's also distinct from hCG, which bypasses the pituitary entirely and acts directly on the testes. Because enclomiphene requires an intact, functioning pituitary and hypothalamus, it's appropriate for secondary hypogonadism — not for primary (testicular) hypogonadism, where the testes themselves can't respond adequately no matter how much LH/FSH stimulation they receive.

In a Phase II pharmacodynamic study testing three doses (6.25, 12.5, and 25 mg), enclomiphene raised testosterone into the normal range within 2 weeks, with effects on LH and testosterone still measurable at least a week after stopping the drug.⁴ Interestingly, testosterone levels followed a roughly physiologic 24-hour pattern — morning peaks, midday dips, rising again at night — closer to the body's natural rhythm than the artificial peak-trough pattern produced by injectable testosterone.⁴ It's taken orally, once daily — a practical advantage over injectable options.

What the research shows

Animal / preclinical evidence

The research brief for enclomiphene does not identify dedicated animal-model efficacy studies; its pharmacology as an estrogen receptor antagonist builds on decades of basic SERM research (including work on clomiphene, its parent compound), but the clinical evidence base described below is drawn entirely from human trials.

Human evidence

The largest and most rigorous dataset comes from two parallel, randomized, double-blind, placebo-controlled Phase III trials (ZA-304 and ZA-305) in 240 overweight or obese men with secondary hypogonadism.³ Both enclomiphene and testosterone gel raised total testosterone, but LH and FSH rose with enclomiphene and fell with testosterone gel — and while testosterone gel caused sperm concentration to drop by as much as 56.6% in one trial arm, enclomiphene increased it by 11.7–15.2%. More men reached normal testosterone on enclomiphene than on gel (60% vs 15%, and 65% vs 35%, across the two trials).

A smaller Phase IIb study comparing enclomiphene to testosterone gel found that after three months, none of the men on testosterone gel had sperm concentrations above 12 million/mL, while no enclomiphene-treated man fell below 75 million/mL — though this trial was open-label, unblinded, and quite small (12–14 men).² A separate randomized Phase II trial confirmed the same pattern: enclomiphene produced testosterone increases similar to topical testosterone but conserved sperm counts, while testosterone did not.⁴

A 2025 meta-analysis of 10 randomized trials found SERM therapy significantly raised testosterone, LH, and FSH versus placebo, with no significant difference in total testosterone compared to testosterone gel — but significantly better LH/FSH response and lower DHT levels (a marker relevant to acne, scalp, and prostate side effects) than gel.⁵ A retrospective study comparing enclomiphene directly to its parent compound, clomiphene, found both raised testosterone to similar degrees (about 87–89% of men reaching eugonadal levels), but only enclomiphene significantly increased FSH, LH, and total motile sperm count.⁶

Honest bottom line: for its specific, narrow endpoints — raising testosterone while preserving fertility over roughly 3–4 months — enclomiphene's trial evidence is genuinely solid, arguably the best evidence base of any compound discussed on this page besides testosterone itself. But most trials are industry-sponsored, run only 12–24 weeks, and enrolled a few hundred participants at most. No enclomiphene trial has ever approached the scale or duration needed to rule out longer-term cardiovascular risk — which is exactly what the FDA cited when it declined to approve the drug.

Typical use and dosing

The pivotal Phase III trials tested 12.5 mg and 25 mg orally once daily, with the 25 mg dose generally producing testosterone increases comparable to or exceeding testosterone gel.³ An earlier Phase II dose-ranging study also tested 6.25 mg, with the 25 mg dose producing the highest average testosterone level at day 42 (604±160 ng/dL).⁴

Pivotal trials ran 12–16 weeks, so there's no published long-term (multi-year) dosing data from controlled trials. Common off-label practice, per secondary clinical sources rather than an approved label, starts at 12.5 mg daily and titrates based on testosterone response at 6–8 weeks.

Safety, side effects, and who should avoid it

In the pooled Phase III data, the most frequently reported side effects — headache, joint pain, weight gain, and upper respiratory infection — each occurred in under 5% of patients and were not significantly more common than with testosterone gel.⁷ Less common effects include visual disturbances (a recognized class effect of SERMs, generally reported at low rates), mood changes, mild blood pressure increases, and elevated estradiol, though typically less than seen with testosterone gel.

No trial reported a serious cardiovascular event rate that prompted early termination, unlike some testosterone trials. Enclomiphene's overall tolerability in the available trials has been described as favorable, but "well-tolerated over 12–24 weeks" is not the same claim as "safe long-term" — that's precisely the gap the FDA identified. There are no major, well-characterized drug-drug interactions documented, though enclomiphene's metabolism has not been as thoroughly studied in public FDA review documents as an approved drug's would be, since it never completed the approval process.

Typical monitoring includes baseline and on-treatment total testosterone, LH, FSH, and estradiol to confirm the expected pattern of rising testosterone alongside rising (not falling) LH/FSH; semen analysis if fertility is a treatment goal; blood pressure checks; and periodic screening for visual symptoms given the SERM class effect.

Regulatory status

Enclomiphene is not FDA-approved for any indication. Repros Therapeutics pursued approval for secondary hypogonadism (as Androxal) through the ZA-series Phase II/III trials, but the FDA issued a Complete Response Letter in 2015, citing concerns about the size of the safety database and unresolved long-term cardiovascular questions.⁹ No enclomiphene product has since gained approval. It is not a DEA-controlled substance.

Enclomiphene currently appears on the FDA's Category 1 Interim Bulks List — substances nominated with enough supporting information for the FDA to evaluate for the formal 503A compounding bulks list, for which the agency does not currently intend enforcement action against compounders while the nomination is pending.¹¹ That's a meaningfully different regulatory posture than hCG, which is excluded from compounding altogether as a reclassified biologic — but it's also not a permanent or finalized status, so it's worth monitoring the FDA's ongoing Pharmacy Compounding Advisory Committee determinations. Clomiphene citrate itself, the FDA-approved racemic parent compound, remains available generically for female ovulation induction and continues to be used off-label in men as a lower-cost alternative.

Frequently asked questions